ZBED6 is not affected in the CRISPR KO cell line, and the delayed tumor growth of HeLa-KO-ZC3 is a strong indication that specific targeting of ZC3H11A can result in a therapeutic effect. This evidence concerns the gene ZC3H11A and neoplasm.